Carryover effects of baloxavir acid in human nasopharyngeal/pharyngeal swabs on infectious titer testing of influenza virus. Issue 3 (28th January 2020)

• Record Type: Journal Article
• Authors: Baba, Keiko; Oka, Ryoko; Shano, Shinya; Omoto, Shinya; Noshi, Takeshi; Shishido, Takao; Naito, Akira; Kawaguchi, Keiko; Ishibashi, Toru; Uehara, Takeki
• Is Part Of: Influenza and other respiratory viruses. Volume 14:Issue 3(2020)
• Page Start: 353
• Page End: 357
• Publication Date: 2020-01-28
• Subjects: baloxavir acid -- baloxavir marboxil -- cap‐dependent endonuclease -- drug carryover -- influenza virus; Influenza -- Periodicals; Respiratory infections -- Periodicals; Virus diseases -- Periodicals; Influenza, Human -- Periodicals; Respiratory Tract Diseases -- Periodicals; Virus Diseases -- Periodicals; Grippe -- Périodiques; Appareil respiratoire -- Infections -- Périodiques; Maladies à virus -- Périodiques; 616.203
• DOI: 10.1111/irv.12721
• Languages: English
• ISSNs: 1750-2640

Abstract

Abstract: Baloxavir marboxil (BXM) demonstrated a rapid and profound decline in infectious viral titer 1 day after BXM administration. Rapid reduction in virus titer is a characteristic of BXM. There may be a possibility that drug carryover effects have impacts on the observed antiviral effects due to the poor correlation that was observed between viral titer reduction and alleviation of influenza symptoms. Here, we report possible carryover effects of baloxavir acid (BXA), an active form of BXM, on infectious titer testing. Our findings indicate that there is little impact of BXA carryover on the infectious titer testing.